Clinical assessment and treatment of diabetes in patients with chronic kidney disease

被引:5
作者
Carretero Gomez, J. [1 ]
Arevalo Lorido, J. C. [1 ]
机构
[1] Hosp Comarcal Zafra, Med Interna Serv, Badajoz, Spain
来源
REVISTA CLINICA ESPANOLA | 2018年 / 218卷 / 06期
关键词
Diabetes; Chronic kidney disease; Diabetic nephropathy; Diabetic kidney disease; CHRONIC-RENAL-FAILURE; CARDIOVASCULAR OUTCOMES; TYPE-2; NEPHROPATHY; LINAGLIPTIN; MELLITUS; INSULIN; EMPAGLIFLOZIN; ALBUMINURIA; SITAGLIPTIN;
D O I
10.1016/j.rce.2018.03.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus type 2 is the main cause of chronic kidney disease. Patients with this disease have higher morbidity and mortality and risk of hypoglycaemia than those without this disease. In 2010, type 2 diabetes was the reason for starting renal replacement therapy in 24.7% of patients. The prevalence of microalbuminuria, proteinuria and a reduced glomerular filtration rate is 36%, 8% and 22%, respectively. The presence of albuminuria is a predictor of chronic kidney disease. Diabetic kidney disease, previously known as diabetic nephropathy, refers to kidney disease caused by diabetes. Renal hyperfiltration is a marker of intraglomerular hypertension and a risk factor for onset and progression. The new antidiabetic drugs, mainly dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter inhibitors and glucagon-like peptide-1 agonists, have been shown to prevent or slow the progression of kidney disease. (C) 2018 Elsevier Espana, S.L.U. and Sociedad Espanola de Medicina Interna (SEMI). All rights reserved.
引用
收藏
页码:305 / 315
页数:11
相关论文
共 53 条
  • [1] Alcazar R, 2008, NEFROLOGIA, V28, P273
  • [2] [Anonymous], 2013, Kidney Int Suppl, DOI [10.1038/kisup.2012.73, DOI 10.1038/KISUP.2012.73]
  • [3] [Anonymous], DIABETES CARE
  • [4] [Anonymous], 2016, FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme
  • [5] Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study
    Banerji, M. A.
    Purkayastha, D.
    Francis, B. H.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 90 (02) : 182 - 190
  • [6] The pharmacokinetics of pioglitazone in patients with impaired renal function
    Budde, K
    Neumayer, HH
    Fritsche, L
    Sulowicz, W
    Stompôr, T
    Eckland, D
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) : 368 - 374
  • [7] Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
    Cornel, Jan H.
    Bakris, George L.
    Stevens, Susanna R.
    Alvarsson, Michael
    Bax, Willem A.
    Chuang, Lee-Ming
    Engel, Samuel S.
    Lopes, Renato D.
    McGuire, Darren K.
    Riefflin, Axel
    Rodbard, Helena Wachslicht
    Sinay, Isaac
    Tankova, Tsvetalina
    Wainstein, Julio
    Peterson, Eric D.
    Holman, Rury R.
    [J]. DIABETES CARE, 2016, 39 (12) : 2304 - 2310
  • [8] Nonproteinuric Diabetic Nephropathy When Diabetics Don't Read the Textbook
    Dwyer, Jamie P.
    Lewis, Julia B.
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2013, 97 (01) : 53 - +
  • [9] Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
    Ferreira, Juan Camilo Arjona
    Marre, Michel
    Barzilai, Nir
    Guo, Hua
    Golm, Gregory T.
    Sisk, Christine McCrary
    Kaufman, Keith D.
    Goldstein, Barry J.
    [J]. DIABETES CARE, 2013, 36 (05) : 1067 - 1073
  • [10] Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
    Green, Jennifer B.
    Bethel, M. Angelyn
    Armstrong, Paul W.
    Buse, John B.
    Engel, Samuel S.
    Garg, Jyotsna
    Josse, Robert
    Kaufman, Keith D.
    Koglin, Joerg
    Korn, Scott
    Lachin, John M.
    McGuire, Darren K.
    Pencina, Michael J.
    Standl, Eberhard
    Stein, Peter P.
    Suryawanshi, Shailaja
    Van de Werf, Frans
    Peterson, Eric D.
    Holman, Rury R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) : 232 - 242